INVENTORY	3 Months Ended
Jun. 30, 2026
Inventory Disclosure [Abstract]
INVENTORY	NOTE 3- INVENTORY As of June 30, 2026, and March 31, 2026, inventory consisted of raw materials and finished goods. Given the nature of our pharmaceutical products, and the storage protocols associated with inventory, compounding activities occur at the time of, or shortly before receipt of customer orders and shipment of finished goods. As of June 30, 2026, and March 31, 2026, the Company’s inventory was comprised of raw materials totaling $767,309 and $612,824, respectively, and finished goods totaling $86,765 and $69,235, respectively.

The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 330
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/330/tableOfContent

Name:	us-gaap_InventoryDisclosureTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration